On June 28, Elaine Blais and Willy Jay, partners at Goodwin Proctor LLP, held a webinar discussing the Supreme Court’s Decision in the case of Sandoz v Amgen. While the court provided some much-needed clarity surrounding requirements of the Biologics Price Competition and Innovation Act “patent dance,” as Blais and Jay pointed out, the court’s ruling left a number of important questions unresolved.
On June 28, Elaine Blais and Willy Jay, partners at Goodwin Proctor LLP, held a webinar discussing the Supreme Court’s Decision in the case of Sandoz v Amgen. While the court provided some much-needed clarity surrounding requirements of the Biologics Price Competition and Innovation Act (BPCIA) “patent dance,” as Blais and Jay pointed out, the court’s ruling left a number of important questions unresolved.
Among key issues raised by Sandoz v Amgen—and not addressed by the court—are those related to state law. The Supreme Court remanded to the federal circuit the questions of whether Sandoz’s conduct was unlawful in the State of California, whether federal law preempts any state-law remedy in the case, and whether Sandoz has forfeited any preemption defense. As Blais and Jay pointed out, we don’t have enough clarity on who will answer these questions: the district court or the federal circuit.
As the industry looks past the particulars of this case and toward implications for the future, and as litigants explore whether state laws can provide an injunctive remedy that federal law does not, the question arises of which state laws will be applied, and who will decide the future of state-law cases.
The court also declined to confront issues of what would happen should an applicant complete only some steps of the patent dance. At several steps of the information exchange process, an applicant’s failure to take action during a prescribed time period can open the door for the reference product’s sponsor to bring an action against the applicant. It is as yet unclear what would become of the sponsor’s ability to bring such actions in the case of an incomplete patent dance.
Additional unresolved questions related to an incomplete information exchange process include what will happen to the 2 phases of BPCIA litigation should a biosimilar applicant terminate the first wave litigation by serving notice of commercial marketing to the reference product’s sponsor. Typically, the second wave of litigation is triggered by such notice, but it is unclear whether the initial wave of litigation would continue in such a scenario, or whether a preliminary injunction be available.
Finally, it remains unclear whether the FDA will participate as an amicus curiae (literally a “friend of the court” who serves as an impartial advisor) to assist in clarifying some of these issues. Anthony Yang, who served as amicus curiae in Sandoz v Amgen, indicated that the FDA had been petitioned to involve itself in creating patent rules, but had declined. Perhaps Justice Stephen Breyer’s request that the FDA make its opinions known in resolving these questions will prompt the agency to break its long silence on patent issues.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.